Effect of PRM-125 on Ambulatory Blood Pressure

PRM Pharma

Status and phase: Withdrawn; Phase 3

Conditions: Hypertension

Treatments: Drug: PRM-125

Study type: Interventional

Funder types: Industry

Identifiers

NCT05195827

CTD-3001

Details and patient eligibility

About

Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults with Hypertension

Full description

Approximately 60 subjects with primary hypertension are treated for 8 weeks with PRM125 to determine if Ambulatory Blood Pressure is changed.

Sex: All

Ages: 30 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• primary hypertension

Exclusion criteria

• medical conditions that preclude evaluation and/or adversely effect subject safety

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

PRM125

Experimental group

Description:

PRM125

Treatment:

Drug: PRM-125